Technical Analysis for ORGS - Orgenesis Inc.

Grade Last Price % Change Price Change
F 1.20 -43.13% -0.91
ORGS closed down 34.84 percent on Friday, October 18, 2024, on 14.62 times normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: Nov 11
*** please verify all earnings dates ***
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish -43.13%
Volume Surge Other -43.13%
Lower Bollinger Band Walk Weakness -43.13%
New 52 Week Low Weakness -43.13%
Wide Bands Range Expansion -43.13%
Below Lower BB Weakness -43.13%
Gapped Down Weakness -43.13%
Oversold Stochastic Weakness -43.13%
NR7 Range Contraction -62.94%
Narrow Range Bar Range Contraction -62.94%

   Recent Intraday Alerts

Alert Time
Possible NR7 about 21 hours ago
60 Minute Opening Range Breakout about 24 hours ago
Gapped Down (Full) 1 day ago
Down 5% 1 day ago
Down 3% 1 day ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Orgenesis Inc. Description

Orgenesis Inc. is a regenerative therapy company. The Company operates through two segments: Contract Development and Manufacturing Organization (CDMO) and Cellular Therapy Business (CTB). The CDMO activity is operated by the Company's subsidiary, MaSTherCell SA, which specializes in cell therapy development for advanced medicinal products. MaSTherCell is providing two types of services to its customers: process and assay development services and good manufacturing practice (GMP) contract manufacturing services. The CTB activity is based on its technology that demonstrates the capacity to induce a shift in the developmental fate of cells from the liver and differentiating (converting) them into pancreatic beta cell-like insulin producing cells for patients with Type I Diabetes. It intends to advance a product that combines cell-based therapy and regenerative medicine, Autologous Insulin Producing (AIP) cells, into clinical development.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Diabetes Clinical Development Stem Cell Cell Therapy Endocrine System Insulin Hormones Regenerative Medicine Contract Manufacturing Peptide Hormones Contract Manufacturing Services Type I Diabetes Assay Development Services Diabetes Mellitus Type 1 Medicinal Product Medicinal Products

Is ORGS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 10.799
52 Week Low 1.9283
Average Volume 32,858
200-Day Moving Average 5.63
50-Day Moving Average 5.73
20-Day Moving Average 3.89
10-Day Moving Average 3.42
Average True Range 0.60
RSI (14) 27.54
ADX 30.78
+DI 13.22
-DI 39.62
Chandelier Exit (Long, 3 ATRs) 3.94
Chandelier Exit (Short, 3 ATRs) 3.74
Upper Bollinger Bands 5.23
Lower Bollinger Band 2.55
Percent B (%b) -0.16
BandWidth 68.84
MACD Line -0.77
MACD Signal Line -0.69
MACD Histogram -0.0758
Fundamentals Value
Market Cap 67.26 Million
Num Shares 31.9 Million
EPS -0.91
Price-to-Earnings (P/E) Ratio -2.32
Price-to-Sales 0.34
Price-to-Book 0.77
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.77
Resistance 3 (R3) 2.79 2.58 2.66
Resistance 2 (R2) 2.58 2.41 2.57 2.63
Resistance 1 (R1) 2.34 2.30 2.46 2.33 2.59
Pivot Point 2.14 2.14 2.19 2.13 2.14
Support 1 (S1) 1.90 1.97 2.02 1.89 1.63
Support 2 (S2) 1.69 1.86 1.69 1.59
Support 3 (S3) 1.46 1.69 1.56
Support 4 (S4) 1.45